QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN

QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN

[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic can...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KENICHI KAWAGUCHI, SUNAO IMADA, HIROKI ISHIOKA, HISAO HAMAGUCHI, TAKAHIRO MORIKAWA, MITSUAKI OKUMURA, KAZUYUKI KURAMOTO, TAKEYUKI NAGASHIMA, TOMOHIRO YOSHINARI, KOHEI INAMURA, EIJI KAWAMINAMI, HIDEYUKI WATANABE, TOMOYOSHI IMAIZUMI
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator KENICHI KAWAGUCHI
SUNAO IMADA
HIROKI ISHIOKA
HISAO HAMAGUCHI
TAKAHIRO MORIKAWA
MITSUAKI OKUMURA
KAZUYUKI KURAMOTO
TAKEYUKI NAGASHIMA
TOMOHIRO YOSHINARI
KOHEI INAMURA
EIJI KAWAMINAMI
HIDEYUKI WATANABE
TOMOYOSHI IMAIZUMI
description [Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a quinazoline compound has an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ZA202307791B</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ZA202307791B</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ZA202307791B3</originalsourceid><addsrcrecordid>eNrjZPAMDPX0c4zy9_H0c1Vw9vcN8A_1c1Fw8w9S8PRzCXX29HNXcHF1D3J0cQzx9PdT8HdTcDc0clHwDQ1x9AtR8A5yDFYICPIPcfX042FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8VGORgZGxgbm5paGTsbEqAEANZstIA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN</title><source>esp@cenet</source><creator>KENICHI KAWAGUCHI ; SUNAO IMADA ; HIROKI ISHIOKA ; HISAO HAMAGUCHI ; TAKAHIRO MORIKAWA ; MITSUAKI OKUMURA ; KAZUYUKI KURAMOTO ; TAKEYUKI NAGASHIMA ; TOMOHIRO YOSHINARI ; KOHEI INAMURA ; EIJI KAWAMINAMI ; HIDEYUKI WATANABE ; TOMOYOSHI IMAIZUMI</creator><creatorcontrib>KENICHI KAWAGUCHI ; SUNAO IMADA ; HIROKI ISHIOKA ; HISAO HAMAGUCHI ; TAKAHIRO MORIKAWA ; MITSUAKI OKUMURA ; KAZUYUKI KURAMOTO ; TAKEYUKI NAGASHIMA ; TOMOHIRO YOSHINARI ; KOHEI INAMURA ; EIJI KAWAMINAMI ; HIDEYUKI WATANABE ; TOMOYOSHI IMAIZUMI</creatorcontrib><description>[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a quinazoline compound has an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.</description><language>eng</language><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20241218&amp;DB=EPODOC&amp;CC=ZA&amp;NR=202307791B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20241218&amp;DB=EPODOC&amp;CC=ZA&amp;NR=202307791B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KENICHI KAWAGUCHI</creatorcontrib><creatorcontrib>SUNAO IMADA</creatorcontrib><creatorcontrib>HIROKI ISHIOKA</creatorcontrib><creatorcontrib>HISAO HAMAGUCHI</creatorcontrib><creatorcontrib>TAKAHIRO MORIKAWA</creatorcontrib><creatorcontrib>MITSUAKI OKUMURA</creatorcontrib><creatorcontrib>KAZUYUKI KURAMOTO</creatorcontrib><creatorcontrib>TAKEYUKI NAGASHIMA</creatorcontrib><creatorcontrib>TOMOHIRO YOSHINARI</creatorcontrib><creatorcontrib>KOHEI INAMURA</creatorcontrib><creatorcontrib>EIJI KAWAMINAMI</creatorcontrib><creatorcontrib>HIDEYUKI WATANABE</creatorcontrib><creatorcontrib>TOMOYOSHI IMAIZUMI</creatorcontrib><title>QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN</title><description>[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a quinazoline compound has an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPAMDPX0c4zy9_H0c1Vw9vcN8A_1c1Fw8w9S8PRzCXX29HNXcHF1D3J0cQzx9PdT8HdTcDc0clHwDQ1x9AtR8A5yDFYICPIPcfX042FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8VGORgZGxgbm5paGTsbEqAEANZstIA</recordid><startdate>20241218</startdate><enddate>20241218</enddate><creator>KENICHI KAWAGUCHI</creator><creator>SUNAO IMADA</creator><creator>HIROKI ISHIOKA</creator><creator>HISAO HAMAGUCHI</creator><creator>TAKAHIRO MORIKAWA</creator><creator>MITSUAKI OKUMURA</creator><creator>KAZUYUKI KURAMOTO</creator><creator>TAKEYUKI NAGASHIMA</creator><creator>TOMOHIRO YOSHINARI</creator><creator>KOHEI INAMURA</creator><creator>EIJI KAWAMINAMI</creator><creator>HIDEYUKI WATANABE</creator><creator>TOMOYOSHI IMAIZUMI</creator><scope>EVB</scope></search><sort><creationdate>20241218</creationdate><title>QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN</title><author>KENICHI KAWAGUCHI ; SUNAO IMADA ; HIROKI ISHIOKA ; HISAO HAMAGUCHI ; TAKAHIRO MORIKAWA ; MITSUAKI OKUMURA ; KAZUYUKI KURAMOTO ; TAKEYUKI NAGASHIMA ; TOMOHIRO YOSHINARI ; KOHEI INAMURA ; EIJI KAWAMINAMI ; HIDEYUKI WATANABE ; TOMOYOSHI IMAIZUMI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ZA202307791B3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>KENICHI KAWAGUCHI</creatorcontrib><creatorcontrib>SUNAO IMADA</creatorcontrib><creatorcontrib>HIROKI ISHIOKA</creatorcontrib><creatorcontrib>HISAO HAMAGUCHI</creatorcontrib><creatorcontrib>TAKAHIRO MORIKAWA</creatorcontrib><creatorcontrib>MITSUAKI OKUMURA</creatorcontrib><creatorcontrib>KAZUYUKI KURAMOTO</creatorcontrib><creatorcontrib>TAKEYUKI NAGASHIMA</creatorcontrib><creatorcontrib>TOMOHIRO YOSHINARI</creatorcontrib><creatorcontrib>KOHEI INAMURA</creatorcontrib><creatorcontrib>EIJI KAWAMINAMI</creatorcontrib><creatorcontrib>HIDEYUKI WATANABE</creatorcontrib><creatorcontrib>TOMOYOSHI IMAIZUMI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KENICHI KAWAGUCHI</au><au>SUNAO IMADA</au><au>HIROKI ISHIOKA</au><au>HISAO HAMAGUCHI</au><au>TAKAHIRO MORIKAWA</au><au>MITSUAKI OKUMURA</au><au>KAZUYUKI KURAMOTO</au><au>TAKEYUKI NAGASHIMA</au><au>TOMOHIRO YOSHINARI</au><au>KOHEI INAMURA</au><au>EIJI KAWAMINAMI</au><au>HIDEYUKI WATANABE</au><au>TOMOYOSHI IMAIZUMI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN</title><date>2024-12-18</date><risdate>2024</risdate><abstract>[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a quinazoline compound has an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_ZA202307791B
source esp@cenet
title QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A04%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KENICHI%20KAWAGUCHI&rft.date=2024-12-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EZA202307791B%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true